The clinical efficacy of CardioGraft-MC^® patches is supported by a growing number of peer-reviewed clinical publications and industry event educational seminars.  In addition to the clinical efficacy of a graft, cost considerations are equally important when deciding on a graft to use for your case as costs do not stop at the index procedure. Reoperations carry a risk of financial burden for patients and facilities, which are often not fully reimbursed for procedures.

The clinical evidence for using cryopreserved allografts in aortic reconstruction confirms that these allografts are an efficacious and safe alternative to synthetic grafts. Whether you are treating an infected synthetic graft, a mycotic aneurysm, an aortoenteric fistula or have a patient who is at a higher risk of infection, we can provide you with the right graft.

Soft-tissue grafts, such as dermis and cardiovascular tissue contain donor cells that can elicit an inflammatory reaction, limiting the effectiveness and long-term durability of the graft.

For over 35 years, LifeNet Health has been the leader in vascular allografts. Our AngioGraft^® allografts deliver the high-quality and proven performance you expect for all of your procedures. The list of articles below demonstrates the efficacy of vascular solutions.